Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae

Last updated: July 27, 2020
Sponsor: Al-Azhar University
Overall Status: Active - Recruiting

Phase

4

Condition

Pneumonia

Treatment

N/A

Clinical Study ID

NCT04489459
D12019
  • Ages > 20
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This prospective, comparative study is evaluating the effectiveness and adverse effects of using colistin at a loading dose of 9 million international units (MIU) followed by 4.5 MIU every 12 h (q12 h) + tigecycline at a loading dose of 100 mg followed by 50 mg every 12 h (q12 h) versus colistin + meropenem 2 g q8 h in treating blood stream infections due to multidrug-resistant (MDR) Klebsiella pneumoniae. The aims of the current study are to investigate and evaluate the therapeutic activity and side effects of Colistin-Meropenem combined therapy versus Colistin-Tigecycline combined therapy in treatment of patients with Multiple Drug Resistant (MDR)-Klebsiella pneumonia bacteraemia The primary goal is comparing 14 day mortality between critically ill patients with MDR Gram-negative Klebsiella pneumoniae infection as evaluation of the therapeutic activity of colistin - tigecycline vs. colistin - meropenem combined therapies. The secondary goal is comparing the comorbidities (nephrotoxicity, hepatotoxicity, neurotoxicity, hematological changes) between critically ill patients with MDR Gram-negative Klebsiella pneumoniae infection who will be treated with colistin - tigecycline versus colistin - meropenem combined therapies.

Method: A total of 60 patients were divided into two groups (30 patients each); the first group received Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h plus Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12 and the second group received Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h plus Intravenous meropenem 2 g IV infusion over 30 minutes q8 h

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with blood stream infection caused by MDR K. pneumoniae, as defined byInfectious Diseases Society of America (IDSA), who were hospitalised in the generalICU, confirmed with carbapenem-resistant K. pneumoniae-positive culture results fromblood sample within the previous 5 days

Exclusion

Exclusion Criteria:

  • All patients without a MDR carbapenem-resistant K. pneumoniae-positive cultureisolated from the blood. In addition, the following patients are excluded: patientswith a Glasgow Coma Scale (GCS) score of <9 in non-ventilated patients or <6 inventilated patients; patients with end-stage metastatic malignant cancer; and allterminal patients with Acute Physiology and Chronic Health Evaluation (APACHE) II orSequential Organ Failure Assessment (SOFA) scores of >34 or >15, respectively, andrisk of mortality >85% or >80% on the first day of colistin administration,respectively [27,28]. Moreover, patients who received i.v. colistin combinationtherapies for <72 h are excluded from further analysis

Study Design

Total Participants: 60
Study Start date:
September 21, 2019
Estimated Completion Date:
July 31, 2020

Connect with a study center

  • Qasr El Ainy

    Cairo,
    Egypt

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.